European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 16(4), 373-378 (2011-12-27)
To determine efficacy and safety of corticosteroid treatment in patients with severe Sydenham's chorea paralytic form. This is a 4 years observational study on ten patient with severe paralytic form of Sydenham's chorea unresponsive to neuroleptics and antiepileptics agents, treated
Orphanet journal of rare diseases, 8, 26-26 (2013-02-15)
Dysferlinopathies are autosomal recessive disorders caused by mutations in the dysferlin (DYSF) gene encoding the dysferlin protein. DYSF mutations lead to a wide range of muscular phenotypes, with the most prominent being Miyoshi myopathy (MM) and limb girdle muscular dystrophy
Siliconosis: autoimmune/inflammatory syndrome induced by adjuvants (ASIA).
Mónica Caldeira et al.
The Israel Medical Association journal : IMAJ, 14(2), 137-138 (2012-06-15)
Quality of life in Duchenne Muscular Dystrophy (DMD) has improved significantly with corticosteroid treatment. However, corticosteroids decrease bone mass and increase vertebral fragility fracture risk. We report on bone health in 39 boys with DMD on long-term deflazacort (0.9 mg/kg/day)
Physical medicine and rehabilitation clinics of North America, 23(4), 821-828 (2012-11-10)
Although prednisone has never been formally approved for use in Duchenne muscular dystrophy (DMD) by regulatory agencies, its efficacy has been confirmed in trials dating from the 1980s. There is a strong need for optimization of both specific type of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.